PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer

Related Clinical Trial
Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome Evaluation of ArTificial Intelligence System (Gi-Genius) for adenoMa dEtection in Lynch Syndrome. DNA Adductomics for Colorectal Cancer Investigation PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancer Faecal Microbiota Characterization in Lynch Syndrome (LS) Patients With or Without Colorectal Neoplasia Evaluating the Cologuard Test for Use in Lynch Syndrome PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation Implementation of the Families Accelerating Cascade Testing Toolkit (FACTT) for Hereditary Breast and Ovarian Cancer and Lynch Syndrome Identifying and Caring for Individuals With Inherited Cancer Syndrome Predictive Factor Study of the Occurrence of Endometrial Cancer in Patients With Lynch Syndrome Liquid Biopsy Evaluation and Repository Development at Princess Margaret Direct Information to At-risk Relatives Family History Study on Cancer Risk Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Biomarkers in Samples From Patients With Endometrial Cancer Genetic Risk: Whether, When, and How to Tell Adolescents Familial Colorectal Cancer Registry in Hispanics Prostate Cancer Screening Among Men With High Risk Genetic Predisposition Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool Pediatric Reporting of Adult-Onset Genomic Results Trial to Compare eConsent With Standard Consent Among Prospective Biobank Participants MSI in Circulatory DNA of Endometrial Cancer Telemedicine vs. Face-to-Face Cancer Genetic Counseling Educational CD-ROM Compared With Standard Informed Consent for Patients With Colorectal Cancer or a Family History of Colorectal Cancer Implementation of a New Strategy to Identify HNPCC Patients Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes The GEOLynch Cohort Study Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care Weight Management and Health Behavior Intervention in Lowering Cancer Risk for BRCA Positive and Lynch Syndrome Families Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE) NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome I-Scan For Colon Polyp Detection In HNPCC Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes Psychosocial Aspects of Genetic Testing for Hereditary Nonpolyposis Colon Cancer Ohio Colorectal Cancer Prevention Initiative Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy Molecular Screening for Lynch Syndrome in Denmark Atorvastatin ± Aspirin in Lynch Syndrome Syndrome Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Uncertain Genetic Test Results for Lynch Syndrome High Definition White-Light Colonoscopy vs. Chromoendoscopy for Surveillance of Lynch Syndrome. Linked Color Imaging Versus High-definition White Light Endoscopy for the Detection of Polyps in Patients With Lynch Syndrome (LCI-LYNCH) Hereditary Nonpolyposis Colorectal Cancer in Taiwan-Related Genetic Study and Clinical Applications Molecular Screening for Lynch Syndrome in Southern Denmark Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer Multi-Organ Screening Recommendations in Patients With Lynch Syndrome Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria Chromoendoscopy to Decrease the Risk of Colorectal Neoplasia in Lynch Syndrome Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting Registry for Women Who Are At Risk Or May Have Lynch Syndrome

Brief Title

PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer

Official Title

PD-1 Antibody as a Sequential Therapy Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer: an Open, Multi-center, Phase II Clinical Trial

Brief Summary

      In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with
      PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal
      cancer staged as locally advanced (cT3-T4N+/-M0 for rectal cancer). This treatment will be
      given during the window period until surgical resection of the tumor.
    


Study Phase

Phase 2

Study Type

Interventional


Primary Outcome

Pathological complete response

Secondary Outcome

 Relapse-free survival (RFS)

Condition

Lynch Syndrome

Intervention

PD-1 antibody

Study Arms / Comparison Groups

 PD-1 antibody + capecitabine + radiation
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

30

Start Date

January 1, 2021

Completion Date

December 31, 2026

Primary Completion Date

December 31, 2024

Eligibility Criteria

        Inclusion Criteria:

          -  Patients who personally provided written consent for participation in the study

          -  Treatment-naive patients with rectal cancer, in whom the inferior margin of the tumor
             was at a distance of 12 cm or less from the AV before CRT

          -  Primary rectal cancer histopathologically confirmed to be adenocarcinoma

          -  Clinical stage of T3,and T4 ,N any,M0,before CRT

          -  Macroscopic radical resection could be feasible, based on diagnostic imaging before
             CRT

          -  Patients with the ECOG performance status of 0 or 1 at the time of enrollment

          -  Patients without distant metastasis on the imaging test before CRT

          -  Preoperative biopsy of tumor immunohistochemistry TPS>1% or CPS>1

          -  Life expectancy of greater than 2 years

          -  No signs of intestinal obstruction; or the obstruction has been relieved after the
             proximal colostomy operation

          -  Hematology: WBC>4000/mm3; PLT>100000/mm3; Hb>10g/dL

          -  Liver function: SGOT and SGPT are less than 1.5 times the normal value; bilirubin is
             less than 1.5mg/dL

          -  Renal function: creatinine <1.8mg/dL Others: non-pregnant or breast-feeding women; no
             other malignant diseases (except for non-melanoma or cervical carcinoma in situ)
             within 5 years or during the same period; no mental illness that causes the inability
             to obtain informed consent; no other serious diseases that can shorten the survival
             time disease.

          -  Have not received rectal surgery in the past;

          -  Have not received chemotherapy or radiotherapy in the past;

          -  Have not received biological treatment in the past;

          -  Past endocrine therapy: unlimited.

        Exclusion Criteria:

          -  Rectal cancer with unstable microsatellite (MSI or dMMR);

          -  Preoperative biopsy of tumor immunohistochemistry TPS≤1% or CPS≤1

          -  Known history of human immunodeficiency virus (HIV) or chronic hepatitis B or C (high
             copy viral DNA);

          -  Autoimmune diseases;

          -  Other active clinical serious infections (>NCI-CTC version 3.0);

          -  Patients in clinical phase I;

          -  There is evidence that there is distant metastasis before surgery;

          -  Cachexia, decompensation of organ function;

          -  Have a history of pelvic or abdominal radiotherapy;

          -  Multiple primary cancers;

          -  Patients who need treatment for seizures (such as steroids or anti-epileptic
             treatment);

          -  Have a known additional malignant tumors within 5 years. Exceptions include basal cell
             carcinoma of the skin that has undergone potentially curative therapy or in situ
             cervical cancer;

          -  Chronic inflammatory bowel disease, intestinal obstruction;

          -  Drug abuse and medical, psychological or social conditions may interfere with
             patients' participation in research or have an impact on the evaluation of research
             results;

          -  Known or suspected to be allergic to the study drug or to any drug given in connection
             with this test;

          -  Any unstable conditions or situations that may endanger patient safety and compliance
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

, 13543478645 Ext. +86, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT04833387

Organization ID

B2019-092


Responsible Party

Principal Investigator

Study Sponsor

Sun Yat-sen University

Collaborators

 Liaoning Tumor Hospital & Institute

Study Sponsor

, , 


Verification Date

April 2021